Please login to the form below

Not currently logged in
Email:
Password:

Vernalis

This page shows the latest Vernalis news and features for those working in and with pharma, biotech and healthcare.

Boston Scientific makes $4.2bn play for UK’s BTG

Boston Scientific makes $4.2bn play for UK’s BTG

The acquisition of BTG follows the buyout of another veteran of the UK biotech scene, Vernalis, which was acquired by Ligand Pharma in August for $33m, Vernalis's chequered history viewed

Latest news

  • Vernalis accepts £33m takeover offer from Ligand Pharma Vernalis accepts £33m takeover offer from Ligand Pharma

    Biotech buyout brings team of 70 scientists in Cambridge, UK. After mulling over several takeover offers, UK biotech Vernalis has been won over by an overture from California’s Ligand Pharma ... If Ligand’s offer is approved by Vernalis shareholders,

  • FDA knocks-back second Vernalis cough and cold treatment FDA knocks-back second Vernalis cough and cold treatment

    Vernalis’ hopes of bringing either of its cough-cold drugs CCP-07 and CCP-08 to the US market in time for the 2017-2018 winter have been dashed. ... Ian Garland, chief executive officer of Vernalis, said: “Unfortunately, the outstanding items that

  • Juno cleared to restart CAR-T trial after deaths Juno cleared to restart CAR-T trial after deaths

    Vipadenant was originally developed as a Parkinson's disease candidate by UK company Vernalis and licensed to Biogen, but its development was held back by safety concerns and Biogen eventually abandoned

  • Merck & Co drops Parkinson's prospect preladenant Merck & Co drops Parkinson's prospect preladenant

    2011. Meanwhile, Lundbeck was also working in this area with its Lu AA47070, but discontinued this project a couple of years ago, while Vernalis and Biogen Idec dropped their own candidate

  • Biogen/ Vernalis call halt to Parkinson's drug

    Biogen and Vernalis are discontinuing development of the drug vipadenant for Parkinson's disease, due to "findings in preclinical toxicology studies". ... Biogen and Vernalis are discontinuing development of the drug vipadenant for Parkinson's disease,

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Corporate acquisition. 245††. Vernalis/  Not disclosed. Adenosine receptor antagonist programme, including the lead drug candidate, V81444.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Keeping the romance under wraps. It was announced in February that Vernalis has licensed its proprietary adenosine receptor antagonist programme, including the phase 1/2 lead compound V81444, for use in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Study Report

Market Study Report is a hub for market intelligence products and services. We streamline the purchase of your market research...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics